Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Ali Tabarroki, MD, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Juraj Bodo, PhD, Li Zhang, Felicitas Lacbawan, Edy Hasrouni, John Barnard, Alan E. Lichtin, Daniel Lindner, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 5259.

https://doi.org/10.1182/blood.V122.21.5259.5259

Published: 2013

Journal Articles

Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments

Valeria Visconte, PhD, Fabiola Traina, MD, PhD, Ali Tabarroki, MD, Edy Hasrouni, Jing Ai, MD, PhD, Matt Kalaycio, MD, Anjali S. Advani, MD, Hien K. Duong, MD, Yogen Saunthararajah, M.D., John Barnard, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 5237.

https://doi.org/10.1182/blood.V122.21.5237.5237

Published: 2013

Journal Articles

LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia

Ramon V. Tiu, MD, Valeria Visconte, PhD, Paul Elson, Michael J. Clemente, Ali Tabarroki, MD, Edy Hasrouni, Amy Porter, Lindsey Mooney, Manuel G. Afable, II, Ricki Englehaupt, Joy Juersivich, RN, MSc, Kathleen Cooper, RN, MSc, Mikkael A. Sekeres, MD, MS, Yogen Saunthararajah, M.D., Jaroslaw P. Maciejewski, MD, PhD

Blood (2013) 122 (21): 3711.

https://doi.org/10.1182/blood.V122.21.3711.3711

Published: 2013

Journal Articles

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Jing Ai, MD, PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Edy Hasrouni, Betty K. Hamilton, MD, Sudipto Mukherjee, MD, PhD, MPH, Matt Kalaycio, MD, Ronald M. Sobecks, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD, MS, Shashirekha Shetty, PhD, Ramon V. Tiu, MD

Blood (2013) 122 (21): 2809.

https://doi.org/10.1182/blood.V122.21.2809.2809

Published: 2013

Journal Articles

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

Blood (2013) 122 (21): 1555.

https://doi.org/10.1182/blood.V122.21.1555.1555

Published: 2013

Journal Articles

Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality

Valeria Visconte, PhD, Ali Tabarroki, MD, Li Zhang, Edy Hasrouni, Chris Gerace, Robyn Frum, Anjali S. Advani, MD, Hien K. Duong, MD, Matt Kalaycio, MD, Yogen Saunthararajah, M.D., Mikkael A. Sekeres, MD, MS, Eric D. Hsi, MD, Shashirekha Shetty, PhD, Heesun J. Rogers, MD, PhD, Ramon V. Tiu, MD

Blood (2013) 122 (21): 2596.

https://doi.org/10.1182/blood.V122.21.2596.2596

Published: 2013

Journal Articles

Inhibition Of JAK-STAT Pathway As a Therapeutic Option For Myelofibrosis Associated Pulmonary Hypertension

Blood (2013) 122 (21): 1585.

https://doi.org/10.1182/blood.V122.21.1585.1585

Published: 2013

Journal Articles

Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes

Ali Tabarroki, MD, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Juraj Bodo, PhD, Li Zhang, Edy Hasrouni, John Barnard, Alan E. Lichtin, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 4063.

https://doi.org/10.1182/blood.V122.21.4063.4063

Published: 2013

Journal Articles

BCL -2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease

Valeria Visconte, PhD, Reda Z Mahfouz, MD/PhD, Ali Tabarroki, MD, Edy Hasrouni, Heesun J. Rogers, MD, PhD, Yogen Saunthararajah, MD, Brian T. Hill, MD, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, John Barnard, Ramon V. Tiu, MD

Blood (2013) 122 (21): 263.

https://doi.org/10.1182/blood.V122.21.263.263

Published: 2013

Journal Articles

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Ali Tabarroki, MD, Li Zhang, Yvonne Parker, Edy Hasrouni, Reda Z Mahfouz, MD/PhD, Quteba Ebrahem, MD, Kyoichi Isono, Haruhiko Koseki, Anjali S. Advani, MD, Yogen Saunthararajah, M.D., Mikkael A. Sekeres, MD, MS, Daniel Lindner, John Barnard, Ramon V. Tiu, MD

Blood (2013) 122 (21): 259.

https://doi.org/10.1182/blood.V122.21.259.259

Published: 2013

Journal Articles

Newly Acquired Molecular Mutations and SNP-A Lesions Alters the Natural History of Trisomy 8 Myeloid Neoplasms

Yang Liu, BA, Paul Elson, ScD, Ali Tabarroki, MD, Valeria Visconte, PhD, Edy Hasrouni, Manoj Bupathi, MD, Betty K. Hamilton, MD, Fabiola Traina, MD, PhD, Hien K. Duong, MD, Heesun J. Rogers, MD, PhD, Yogen Saunthararajah, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD, MS, Ramon V Tiu, MD

Blood (2012) 120 (21): 312.

https://doi.org/10.1182/blood.V120.21.312.312

Published: 2012

Journal Articles

A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN

Yang Liu, BA, Ali Tabarroki, MD, Valeria Visconte, PhD, Edy Hasrouni, Manoj Bupathi, MD, Betty K. Hamilton, MD, Fabiola Traina, MD, PhD, Hien K. Duong, MD, Heesun J. Rogers, MD, PhD, Yogen Saunthararajah, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2012) 120 (21): 1701.

https://doi.org/10.1182/blood.V120.21.1701.1701

Published: 2012

Journal Articles

SF3B1 , a Splicing Factor Gene, Is Infrequently Mutated in Rare Bone Marrow Failure Diseases but Still Associated with Ring Sideroblast Phenotype

Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Ali Tabarroki, MD, Edy Hasrouni, Fabiola Traina, MD, PhD, Yang Liu, Christine L. O'Keefe, PhD, Jaroslaw P. Maciejewski, MD, PhD, Mikkael A. Sekeres, MD, MS, Fred H. Hsieh, MD, Ramon V Tiu, MD

Blood (2012) 120 (21): 3485.

https://doi.org/10.1182/blood.V120.21.3485.3485

Published: 2012

Journal Articles

Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, MD, Ali Tabarroki, MD, Valeria Visconte, PhD, Edy Hasrouni, Hideki Makishima, MD, PhD, Shawnda Tench, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Hien K. Duong, MD, Brian T. Hill, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD, Brian J. Bolwell, MD, Edward A. Copelan, MD, Ramon V. Tiu, MD

Blood (2012) 120 (21): 1973.

https://doi.org/10.1182/blood.V120.21.1973.1973

Published: 2012

Journal Articles

Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts

Blood (2012) 120 (21): 922.

https://doi.org/10.1182/blood.V120.21.922.922

Published: 2012

Journal Articles

Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML)

Edy Hasrouni, Valeria Visconte, PhD, Ali Tabarroki, MD, Heesun J. Rogers, MD, PhD, Fabiola Traina, MD, PhD, Anna Jankowska, MSC, Yang Liu, Betty K. Hamilton, MD, Manoj Bupathi, MD, Hideki Makishima, MD, PhD, Andres Jerez, MD, PhD, Edward A. Copelan, MD, Anjali Advani, MD, Michael A McDevitt, MD, PhD, Matt Kalaycio, MD, Yogen Saunthararajah, MD, Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Ramon V. Tiu, MD

Blood (2012) 120 (21): 3791.

https://doi.org/10.1182/blood.V120.21.3791.3791

Published: 2012

Journal Articles

Molecular Mutations in U2AF1 Are Most Commonly Found in Del20q Myelodysplastic Syndromes but Do Not Lead to Poor Prognosis in This Karyotypic Subtype

Ali Tabarroki, MD, Li Zhang, PhD, Valeria Visconte, PhD, Manoj Bupathi, MD, Heesun J. Rogers, MD, PhD, Hideki Makishima, MD, PhD, Fabiola Traina, MD, PhD, Betty K. Hamilton, MD, Edy Hasrouni, Michael J. Clemente, Paula de Melo Campos, MD, Hien K. Duong, MD, Anjali Advani, MD, Mikkael A. Sekeres, MD, MS, Edward A. Copelan, MD, Ramon V. Tiu, MD

Blood (2012) 120 (21): 3804.

https://doi.org/10.1182/blood.V120.21.3804.3804

Published: 2012

Journal Articles

The Molecular and Cytokine Profile of Triple-Negative ( JAK2 V617F, JAK2 exon 12, MPL negative) Myelofibrosis, a Myeloproliferative Neoplasm with Distinct Clinico-Pathologic Characteristics

Ali Tabarroki, MD, Heesun J. Rogers, MD, PhD, Valeria Visconte, PhD, Edy Hasrouni, Anjali Advani, MD, Mikkael A. Sekeres, MD, MS, Hien K. Duong, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Brady L Stein, MD, Ramon V. Tiu, MD

Blood (2012) 120 (21): 3805.

https://doi.org/10.1182/blood.V120.21.3805.3805

Published: 2012

Journal Articles

Patients with SF3B1 Mutation Have Good Prognosis Even in the Presence of Other Poor Prognostic MDS Features and Have Better Outcomes During Treatment with Low Intensity Chemotherapy

Valeria Visconte, PhD, Ali Tabarroki, MD, Edy Hasrouni, Yang Liu, Betty K. Hamilton, MD, Craig A. Portell, MD, Edward A. Copelan, MD, Anjali Advani, MD, Mikkael A. Sekeres, MD, MS, Ramon V Tiu, MD

Blood (2012) 120 (21): 3831.

https://doi.org/10.1182/blood.V120.21.3831.3831

Published: 2012

NARROW

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments

LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality

Inhibition Of JAK-STAT Pathway As a Therapeutic Option For Myelofibrosis Associated Pulmonary Hypertension

Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes

BCL -2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Newly Acquired Molecular Mutations and SNP-A Lesions Alters the Natural History of Trisomy 8 Myeloid Neoplasms

A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN

SF3B1 , a Splicing Factor Gene, Is Infrequently Mutated in Rare Bone Marrow Failure Diseases but Still Associated with Ring Sideroblast Phenotype

Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation

Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts

Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML)

Molecular Mutations in U2AF1 Are Most Commonly Found in Del20q Myelodysplastic Syndromes but Do Not Lead to Poor Prognosis in This Karyotypic Subtype

The Molecular and Cytokine Profile of Triple-Negative ( JAK2 V617F, JAK2 exon 12, MPL negative) Myelofibrosis, a Myeloproliferative Neoplasm with Distinct Clinico-Pathologic Characteristics

Patients with SF3B1 Mutation Have Good Prognosis Even in the Presence of Other Poor Prognostic MDS Features and Have Better Outcomes During Treatment with Low Intensity Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only